Hussman Strategic Advisors Inc. Trims Stake in Pediatrix Medical Group, Inc. $MD

Hussman Strategic Advisors Inc. lessened its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 20.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 168,000 shares of the company’s stock after selling 42,000 shares during the quarter. Hussman Strategic Advisors Inc.’s holdings in Pediatrix Medical Group were worth $2,814,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in MD. Allianz Asset Management GmbH increased its position in Pediatrix Medical Group by 159.1% during the 2nd quarter. Allianz Asset Management GmbH now owns 61,412 shares of the company’s stock worth $881,000 after purchasing an additional 37,712 shares in the last quarter. Hsbc Holdings PLC boosted its stake in shares of Pediatrix Medical Group by 226.6% during the 2nd quarter. Hsbc Holdings PLC now owns 111,997 shares of the company’s stock worth $1,591,000 after purchasing an additional 77,704 shares during the last quarter. Edgestream Partners L.P. purchased a new stake in shares of Pediatrix Medical Group during the second quarter worth about $763,000. Wedge Capital Management L L P NC acquired a new position in shares of Pediatrix Medical Group in the third quarter valued at approximately $2,315,000. Finally, Wakefield Asset Management LLLP purchased a new position in shares of Pediatrix Medical Group during the second quarter valued at approximately $1,002,000. 97.71% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, Director Michael A. Rucker sold 10,478 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $23.00, for a total transaction of $240,994.00. Following the completion of the sale, the director directly owned 59,101 shares in the company, valued at $1,359,323. The trade was a 15.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the completion of the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. The trade was a 7.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 43,478 shares of company stock valued at $972,924 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Pediatrix Medical Group Price Performance

Shares of Pediatrix Medical Group stock opened at $20.55 on Wednesday. The business’s fifty day moving average price is $22.31 and its 200 day moving average price is $18.60. Pediatrix Medical Group, Inc. has a twelve month low of $11.84 and a twelve month high of $24.99. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $1.76 billion, a P/E ratio of 10.81 and a beta of 0.73.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.21. The company had revenue of $492.88 million for the quarter, compared to the consensus estimate of $476.45 million. Pediatrix Medical Group had a return on equity of 20.45% and a net margin of 8.44%.The company’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same period last year, the business posted $0.44 EPS. As a group, research analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MD has been the subject of several recent analyst reports. Truist Financial lifted their target price on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Zacks Research downgraded Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 23rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 4th. Finally, UBS Group lifted their price target on Pediatrix Medical Group from $16.50 to $23.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. One research analyst has rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $21.00.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.